For the 2026 Non-neurogenic Male LUTS Guidelines, new and relevant evidence was identified, collated and appraised through a structured assessment of the literature for all sections of the Guidelines. Key changes include:
- Minor updates throughout Chapter 4 on diagnostic evaluation, including a new Section 4.15 discussing prostate cancer (PCa).
- Updates throughout the text in Section 5.1 on conservative treatment, including the update on the strength rating for β3 agonists.
- Addition and deletion of subsections in Section 5.3 on the surgical treatment of BPO, with special attention
- to alternative enucleation techniques and alternative ablative techniques as well as new Sections 5.3.5.c.2
- and 5.3.5.c.3.
- Addition of recommendations for management of male urinary incontinence (UI), both for diagnosis and
- conservative treatment.
- New Figure 7 on the management of detrusor underactivity (DU).
- New Section 5.8, on voiding dysfunction in young men.